Time Restricted Eating for Multiple Sclerosis

(Meal Time MS Trial)

BC
Overseen ByBrooks C Wingo, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to learn if the time an individual eats each day impacts neurological health in people with multiple sclerosis. The main questions the investigators are asking are:

1. Does meal timing affect biomarkers of neuronal health (neurofilament light chain \[NfL\] and BDNF) and inflammation (IL-6, IL-17, TNF-ɑ) in adults with MS.

2. Does meal timing affect expression of circadian clock genes and genes associated with autophagy in adults with MS.

Participants will be instructed to start and stop eating at specific times each day based on their group assignment and their personal schedule. They will respond to prompts sent to them on their smartphone to record the times they start and stop eating each day.

As a secondary goal, the study will also explore the feasibility of including translocator protein (TSPO)-PET imaging of neuroinflammation in future clinical trials of TRE in people with MS. To accomplish this, imaging will be completed in a subset of 8 participants at the beginning and end of the study.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with RRMS or SPMS.
I have been on the same disease-modifying therapy for at least 6 months.
* Access to a smartphone
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are assigned to either a Time Restricted Eating group or an Unrestricted Eating group for 12 weeks

12 weeks
Daily self-reporting via smartphone prompts

Imaging Sub-study

A subset of participants undergoes TSPO-PET imaging to assess neuroinflammation

12 weeks
2 visits (in-person) for imaging at baseline and end of study

Follow-up

Participants are monitored for changes in circadian gene expression and autophagy gene expression

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Time Restricted Eating
  • Unrestricted eating

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Time Restricted EatingExperimental Treatment1 Intervention
Group II: Unrestricted EatingActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

Paralyzed Veterans of America Research Foundation

Collaborator

Trials
2
Recruited
50+